Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000947871-21-000243
Filing Date
2021-02-19
Accepted
2021-02-18 21:48:23
Documents
3
Group Members
ORBIMED ADVISORS ISRAEL II LTDORBIMED CAPITAL GP V LLCORBIMED CAPITAL GP VI LLCORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIPORBIMED ISRAEL GP II, L.P.ORBIMED ISRAEL GP LTD.

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 3 ss192645_sc13da.htm SC 13D/A 167728
2 JOINT FILING AGREEMENT ss192645_ex9901.htm EX-99.1 14737
3 FORM OF LOCK-UP AGREEMENT ss192645_ex9904.htm EX-99.4 29410
  Complete submission text file 0000947871-21-000243.txt   213727
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

EIN.: 133976876 | State of Incorp.: DE
Type: SC 13D/A

Mailing Address 500 BOYLSTON STREET 12TH FLOOR BOSTON MA 02116
Business Address 500 BOYLSTON STREET 12TH FLOOR BOSTON MA 02116 617-482-2333
Adicet Bio, Inc. (Subject) CIK: 0001720580 (see all company filings)

EIN.: 813305277 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-90283 | Film No.: 21651879
SIC: 2834 Pharmaceutical Preparations